Document:

Exhibit
10.18

 

POINT
Biopharma Corp.

22 St. Clair Ave. East, Suite 1201, 

Toronto, ON M4T 2S3

 

Donna Husack

 

POINT Biopharma Corp. Employment Agreement

 

March 9, 2021

     

     

    

POINT
Biopharma Corp. Employment Agreement

 

to be effective as of and from

the Effective Date (as defined below)

 

PRIVATE
AND CONFIDENTIAL

 

Donna Husack

140 Burnet Street

Oakville, ON L6K 1C2

 

Dear Donna:

 

		Re:	Terms of Employment of Donna Husack (“you” or the “Employee”)
with POINT Biopharma Corp. (the “Company”)

 

This Agreement (as defined below) sets out the
terms and conditions of your employment by the Company and will constitute your employment agreement.

 

For and in consideration of the promises herein and
other valuable consideration, the parties agree as follows:

 

Article
1 Interpretation

 

		1.1	Definitions

 

For the purposes of this Agreement:

 

		1.1.1	“$” means CDN dollars.

 

		1.1.2	“Affiliate”
means with respect to a Person, any Person that, directly or indirectly, Controls, is Controlled by, or is under common Control
with such Person, including, without limitation, any partner, officer, director, or member of such Person and any venture capital
fund now or hereafter existing that is Controlled by or under common Control with one or more general partners or shares the same
management company or investment manager with such Person, and including any parent or subsidiary company of such Person.

 

		1.1.3	“Agreement” means this employment agreement
and the exhibits hereto.

 

		1.1.4	“Base Salary” shall have the meaning set
out in Section 3.2 (Base Salary).

 

		1.1.5	“Business” means the business of the Company
described in Exhibit 1.1.5.

    2 

     

    

		1.1.6	“Business Information” means all business information, including information regarding:

 

		.1	commercial strategies, business plans, business methods, corporate plans, management systems, finances, new business opportunities,
marketing or sales of any past, present or future product or service, including, without limitation, sales targets and statistics,
market share and pricing statistics, marketing surveys and plans, market research reports, sales techniques, price lists, discount
structures, advertising and promotional material;

 

		.2	financial information, compensation and investment arrangements, terms of agreements, financial structure, financial position,
financial results or other financial affairs, actual or proposed transactions or investments or other confidential information;
and

 

		.3	the name, address, telephone number, contact name and identity of each of the Key Contacts, the nature of their business operation,
and all confidential aspects of their business relationship or potential business relationship with the Company or any Affiliate
of the Company.

 

		1.1.7	“Cause” shall have the meaning set out in Section 6.6 (Termination by Company for Cause).

 

		1.1.8	“Change of Control” shall be deemed to have occurred if any of the following occurs after the Effective
Date and before the Termination Date:

 

		.1	any “person” or “group” (as such terms are defined below) is or becomes the “beneficial owner”
(as defined below, except that a “person” or “group” shall be deemed to have “beneficial ownership”
of all shares of capital stock or other equity interests if such person or group has the right to acquire such shares or interests,
whether such right is exercisable immediately or only after the passage of time), directly or indirectly, in a transaction or series
of related transactions, of shares of capital stock or other interests (including partnership interests) of the Company then outstanding
and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers
or similar supervisory positions (“Voting Stock”) of the Company representing more than fifty percent (50%)
of the total voting power of all outstanding classes of Voting Stock; or;

 

		.2	a sale of substantially all of the assets of the Company; or

    3 

     

    

		.3	the Company enters into a merger, reverse-merger, amalgamation, arrangement, consolidation or other form of business combination,
share exchange, reorganization, recapitalization, transfer or other similar transaction with another Person (whether or not the
Company the surviving entity) and as a result of such transaction (a) the members of the board of directors of the Company immediately
prior to such transaction constitute less than a majority of the members of the board of directors of the Company or such surviving
entity immediately following such transaction or (b) the Persons that beneficially owned, directly or indirectly, the shares of
Voting Stock of the Company immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of
Voting Stock of the Company representing at least a majority of the total voting power of all outstanding classes of Voting Stock
of the surviving entity immediately following such transaction.

 

Notwithstanding the foregoing, a Change of Control resulting
from a Financing or from corporate changes between Company Affiliates is deemed not to be a Change of Control for the purposes
of this Agreement.

 

		1.1.9	“Confidential Information” means all non-public
information, knowledge, or data pertaining to the business, affairs and technology of the Company or any Affiliate of the Company,
including:

 

		.1	Technical Information and Business Information;

 

		.2	your Work Product; and

 

		.3	information secured by the Company from Persons subject to an obligation of confidentiality;

 

and, in all cases, all copies and tangible embodiments
thereof, in whatever form or medium, all whether furnished or prepared before or after the Effective Date.

 

		1.1.10	“Control” or “Controls”
means, in relation to a corporation or a partnership, as the case may be:

 

		.1	the right to cast a majority of the votes that may be cast at a general meeting of the shareholders of a corporation;

 

		.2	the right to elect or appoint, directly or indirectly, a majority of the directors of a corporation;

 

		.3	to hold more than 50% of the interests of a partnership other than a limited partnership; and

 

		.4	to be the general partner of a limited partnership.

 

		1.1.11	“Effective
Date” shall have the meaning set out in Section 2.4

 

		1.1.12	“Financing” means capital secured for, and
accepted by, the Company including without limitation through any purchase, transfer or other disposition of any debt, equity or
other securities of the Company.

 

		1.1.13	“Inventions” means any and all discoveries,
developments, enhancements, improvements, concepts, formulas, processes, ideas, writings, whether or not reduced to practice, industrial
and other designs, patents, patent applications, provisional patent applications, continuations, continuations-in-part, substitutions,
divisionals, reissues, renewals, re-examinations, extensions, supplementary protection certificates or the like, trade secrets
or utility models, copyrights and other forms of intellectual property including all applications, registrations and related foreign
applications filed and registrations granted thereon.

    4 

     

    

		1.1.14	“Key Contacts” means the actual and potential: licensors, licensees, sublicensees, collaborators, partners,
investors, shareholders, acquirers, lenders or merger candidates, suppliers and customers of the Company or any Affiliate of the
Company.

 

		1.1.15	“Notice Period” shall have the meaning set out in Section 6.1 (Termination by Employee)

 

		1.1.16	“Objectives” shall have the meaning set out in Section 3.3 (Annual Bonus)

 

		1.1.17	“Option Agreement” shall have the meaning set out in Section 3.5 (Stock Options).

 

		1.1.18	“Person” means any individual, partnership, joint venture, syndicate, sole proprietorship, company or corporation
with or without share capital, trust, trustee, executor, administrator, or other legal personal representatives, regulatory body
or agency, government or governmental agency, authority or entity howsoever designated or constituted.

 

		1.1.19	“Technical Information” means all technical information of the Company or any Affiliate of the Company,
including information regarding knowledge or data of an intellectual, technical, scientific or industrial nature, including compositions
of matter, techniques, specifications, standards, technical data, uses of matter, practices, methods, computer data, scientific
strategies and concepts, clinical and regulatory strategies and concepts, test data, research data, analytical and quality control
data, formulation data, manufacturing data, development information, filings for the protection of intellectual property protection,
drawings, specifications, designs, plans, proposals, reports, formulas, compilations, research data and manuals.

 

		1.1.20	“Term of Employment” means the period from the Effective Date until the date on which your employment with
the Company ceases in accordance with Article 6.

 

		1.1.21	“Termination Date” shall have the meaning set out in Section 6.7.

 

		1.1.22	“Vice President Human Resources” shall
                                         have the meaning set out in Section 2.1 (Position and Duties).

 

		1.1.23	“Work Product” means any and all works
                                         of authorship, including

 

		.1	all Inventions and possible Inventions relating to the Company’s Business resulting from any work performed by you for
the Company that you may invent or co-invent during your involvement in any capacity with the Company, except those Inventions
invented by you entirely on your own time that do not relate to the Company’s Business or do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, by you from or through your
involvement in any capacity with the Company; and

 

		.2	all Technical Information and Business Information resulting from any work performed by you for
the Company; and includes all analyses, compilations, studies, reports or other documents prepared by you based upon or including
any such information, data or knowledge of the Company or any Affiliate of the Company.

    5 

     

    

Article
2 Position, Duties and Service

 

		2.1	Position and Duties

 

You will be employed by and will serve the Company, having the
duties and functions customarily performed by, and having all responsibilities customary to, Vice President Human Resources, including
those described in Exhibit 2.1.

 

You will report directly to the Chief Executive Officer of the
Company. The rights of the Company as provided in this Agreement may be exercised on behalf of the Company only by the Chief Executive
Officer, Board, or by a committee or person expressly designated for such purposes by the Board.

 

		2.2	Changes to Duties

 

Your duties and functions pertain to the Company or any Affiliate
of the Company and may be varied or added to from time to time by the Chief Executive Officer and the Board in its discretion.

 

		2.3	Service to the Company

 

During the Term of Employment, you will:

 

		2.3.1	well and faithfully serve the Company, at all times act in the best interests of the Company, and, to the extent necessary
to discharge the responsibilities assigned to you hereunder, you will use your best efforts to perform faithfully and efficiently
such responsibilities;

 

		2.3.2	apply your skill and experience to the performance of your duties in such employment;

 

		2.3.3	comply with all policies and procedures from time to time formulated by the Company;

 

		2.3.4	devote all of your working time, attention and energies to the business and affairs of the Company; and

 

		2.3.5	not, without the prior approval of the Company, carry on or engage in any other business or occupation or become a director,
officer, employee or agent of or hold any position or office with any other company, firm or person other than the Company, except
as disclosed in Exhibit 2.3.5 or as a volunteer for a non-profit organization, engaging in civic, religious, educational or other
community activities, or maintaining personal investments or a personal holding company, provided that such activities do not materially
interfere with the performance of your duties under this Agreement.

    6 

     

    

		2.4	Term

 

The terms and conditions of this Agreement shall
have effect as and from March 9, 2021 (the “ Effective Date”)
and throughout the Term of Employment. You agree that your service with any prior employer shall not be included in the calculation
of the length or period of your employment with the Company, except as may be required by the Ontario Employment
Standards Act, 2000 and the regulations enacted thereunder, each as amended (the “ESA”).

 

Article
3 Compensation Generally

 

		3.1	No Other Compensation or Benefits

 

You will be compensated as set out in this Article. Unless otherwise
agreed by the parties in writing, you expressly acknowledge and agree that you will not be entitled by reason of your employment
by the Company or by reason of any termination of such employment, to any remuneration, compensation, severance, damages or benefits
other than as expressly set forth in this Agreement, the Option Agreement and as expressly required by applicable employment standards
legislation, including the ESA.

 

		3.2	Base Salary

 

During the Term of Employment, the Company will pay you an annual
base salary (the “Base Salary”) at the rate
of $215,000 per annum, payable on a bi-weekly basis (26 pay periods), subject to applicable withholdings and deductions. The Base
Salary will be reviewed on an annual basis, or as otherwise determined by the Company. Any merit increases are subject to the approval
and discretion of the Board. As an employee whose work is supervisory and/or managerial in character (although you may perform
non-supervisory and/or non-managerial tasks on an irregular or exceptional basis), you are not eligible to be paid overtime pay
or to take lieu time, except as may be specifically required by the ESA.

 

		3.3	Annual Bonus

 

An annual bonus will be in effect, and is based on you meeting
established performance objectives and due 30 days after the board has approved the corporate yearend financial statements.
During the Term of Employment, you will be eligible for a target cash bonus of up to twenty-five percent (25%) of your Base Salary
under this Agreement if the Board (or the Company’s Compensation Committee), in its sole discretion, determines that the
Company has met its short-term and long-term business performance objectives and that you have met your personal performance objectives
(together, the “ Objectives”), which Objectives
will be established on an annual basis by the CEO and Board (or the Company’s Compensation Committee) in consultation with
you. Payment of the performance bonus (less all applicable statutory deductions by the Company) will be made to you once approved
by the Board (or Company’s Compensation Committee), and within 30 days after the Board has approved the corporate yearend
financial statements, provided that, except as otherwise set out in this Agreement, at the time of such approval, you hold current
active employment status with the Company. You acknowledge that participation in any incentive or bonus plan during any one year
confers no rights upon you or any obligations on the Company to continue the plan or entitle you to participate in the plan in
succeeding years. Except only as expressly required by applicable employment standards legislation, including the ESA, no incentives
or bonuses will be paid or are payable to you following the Termination Date and you waive any entitlement to damages in lieu thereof
whether pursuant or attributable to any common law notice period or otherwise.

    7 

     

    

		3.4	Signing Incentives

 

Subject to the approval of Board of Point BioPharma Inc. (the
 “Parent”), you will be granted a nonqualified option to purchase 2,500 shares of the shares of Parent (the
 “Option”), subject to the terms and conditions applicable to options granted under the Equity Incentive Plan
and the stock option agreement (together with the Equity Incentive Plan, the “Option Agreement”). The exercise
price per share of the Option will be equal to the fair market value per share of the Parent’s Common Stock on the date
the Option is granted, as determined by the Parent Board.

 

		3.5	Stock Options in the Event of a Change of Control

 

Subject to the terms and conditions of the Option Agreement,
in the event that as of the date of a Change of Control, you hold unvested stock options that had been granted to you under the
Option Agreement, such unvested stock options shall immediately vest and shall be exercisable in accordance with the terms and
conditions of the Option Agreement.

 

		3.6	Reimbursement for Expenses

 

As of the Effective Date, the Company agrees to reimburse you
for reasonable travelling and other expenses actually and properly incurred in the course of employment. For all such expenses,
you will be required to keep proper accounts and to furnish such statements and vouchers to the Company.

 

		3.7	Vacation

 

During the Term of Employment, you will be entitled to twenty
(20) working days’ vacation, pro-rated for any partial year of employment. The Company reserves the right to request that
vacations be scheduled so as not to conflict with business needs. While you must take at least your minimum statutory entitlement
to vacation each year, any unused vacation balance remaining at calendar year end in excess of minimum statutory vacation entitlements
may be carried over into the subsequent calendar year to a cumulative maximum not exceeding forty (40) working days of vacation.
Subject to applicable employment standards legislation, including the ESA, any vacation carried over in excess of forty (40) days
will be forfeited.

 

		3.8	Benefits

 

During the Term of Employment, the Company will provide for
group health, drugs, dental, vision and life insurance benefits through a mutually agreeable arrangement as is made available to
its executives from time to time. You hereby acknowledge that coverage under any benefit plan, or alternate plan arrangement as
agreed upon in effect from time to time is subject to availability and other requirements of the applicable insurer and that the
components of the benefits plan may be amended, modified or terminated from time to time by the Company in its sole discretion,
and that this may include terminating or changing carriers.

    8 

     

    

Article
4 Intellectual Property Rights

 

		4.1	Obligation of Confidentiality

 

You understand and agree that in the course of your employment
with the Company, both before and after the Effective Date, you have obtained and will obtain knowledge of Confidential Information.
You agree that unless the Company otherwise agrees in writing or except as required by law or disclosed pursuant to a confidential
disclosure agreement executed by the Company and the recipient:

 

		4.1.1	you will keep all Confidential Information learned or acquired by you, disclosed to you or developed by you, as a result of
or in connection with or during the course of your employment by the Company, whether before or after the Effective Date, strictly
confidential;

 

		4.1.2	all Confidential Information shall, as between you and the Company, be and remain the property of the Company; and

 

		4.1.3	you will not at any time, during or after your employment with the Company, disclose any Confidential Information to any Person
other than the Company, or use any Confidential Information for the benefit of any Person other than the Company.

 

The above obligations with respect to Confidential Information
shall not apply to Confidential Information which has become available to the general public through no fault of your own.

 

		4.2	Disclosure of Work Product

 

You agree to promptly and fully inform the Company of all of
your Work Product, whether or not patentable, throughout the course of your involvement, in any capacity, with the Company or any
Affiliate of the Company, whether or not developed before or after your execution of this Agreement. On your ceasing to be employed
by the Company, you will immediately deliver up to the Company all of your Work Product. You further agree that all of your Work
Product shall at all times be the Confidential Information of the Company.

 

		4.3	Assignment of Rights

 

You will assign, and do hereby assign, to the Company or, at
the option of the Company and upon notice from the Company, to the Company’s designee, your entire right, title and interest
in and to all of your Work Product and all other rights and interests of a proprietary nature in and associated with your Work
Product, including all patents, copyrights, trademarks, and applications filed therefore and other registrations granted thereon.
To the extent that you retain or acquire legal title to any such rights and interests, you hereby declare and confirm that such
legal title is and will be held by you only as trustee and agent for the Company. You agree that the Company’s rights hereunder
shall attach to all of your Work Product, notwithstanding that it may be perfected or reduced to specific form after you have terminated
your relationship with the Company. You further agree that the Company’s rights hereunder shall extend to every country of
the world.

    9 

     

    

		4.4	Moral Rights

 

You agree to, and do hereby waive, in whole all moral rights
and agree never to assert any moral rights which you may have in your Work Product, including, without limitation, the right to
the integrity of such Work Product, the right to be associated with the Work Product, the right to restrain or claim damages for
any distortion, mutilation or other modification or enhancement of the Work Product and the right to restrain, the use or reproduction
of the Work Product in any context and in connection with any product, service, cause or institution and you further confirm that
the Company may use or alter any such Work Product as the Company sees fit in its absolute discretion.

 

		4.5	Goodwill

 

You hereby agree that all goodwill you have established or may
establish with Key Contacts relating to the business or affairs of the Company or any Affiliate of the Company, both before and
after the Effective Date, shall, as between you and the Company, be and remain the property of the Company exclusively, for the
Company to use, alter, vary, adapt and exploit as the Company shall determine in its discretion.

 

		4.6	Assistance

 

You hereby agree to assist the Company, at the Company’s
request and expense, both during your Term of Employment and at all times after termination of your Term of Employment for any
reason whatsoever, in:

 

		4.6.1	making patent applications for your Work Product, including instructions to lawyers and/or patent agents as to the characteristics
of your Work Product in sufficient detail to enable the preparation of a suitable patent specification, to execute all formal documentation
incidental to an application for letters patent and to execute assignment documents in favor of the Company for such applications;

 

		4.6.2	making applications for all other forms of intellectual property registration relating to your Work Product;

 

		4.6.3	prosecuting and maintaining the patent applications and other intellectual property relating to your Work Product; and

 

		4.6.4	registering, maintaining and enforcing the patents and other intellectual property registrations relating to your Work Product.

 

		4.7	Assistance with Proceedings

 

You further agree to lend such assistance as you can, at the
Company’s request and expense, in connection with any enforcement of the Company’s intellectual property rights or
defense to an allegation of infringement of another Person’s intellectual property rights, invalidity proceedings respecting,
opposition to, or intervention regarding any applications for letters patent, copyright or trademark or other proceedings relating
to intellectual property or applications for registration thereof.

    10 

     

    

Article
5 Conflicts and Restrictive Covenant

 

		5.1	Disclosure of Conflicts of Interest

 

During your employment with the Company, you will promptly,
fully and frankly disclose to the Company in writing:

 

		5.1.1	the nature and extent of any interest you have or may have, directly or indirectly, in any contract or transaction or proposed
contract or transaction of or with the Company or any Affiliate of the Company or any Key Contact;

 

		5.1.2	every office you may hold or acquire, and every property you may possess or acquire, whereby directly or indirectly, a duty
or interest might be created in conflict with the interests of the Company or any Affiliate of the Company, or your duties and
obligations under this Agreement; and

 

		5.1.3	the nature and extent of any conflict referred to in Sections 5.1.1 and 5.1.2.

 

		5.2	Avoidance of Conflict of Interest

 

You acknowledge that it is the policy of the Company that all
interests and conflicts of the sort described in Section 5.1 (Disclosure of Conflicts of Interest) be avoided, and you agree to
comply with all policies and directives of the Company from time to time regulating, restricting or prohibiting circumstances giving
rise to interests or conflicts of the sort described in Section 5.1. During your employment with the Company, you shall not enter
into any agreement, arrangement or understanding with any other Person that would in any way conflict or interfere with this Agreement
or your duties or obligations under this Agreement or that would otherwise prevent you from performing your obligations hereunder,
and you represent and warrant that you have not prior to the Effective Date entered into any such agreement, arrangement or understanding.

 

		5.3	Restrictive Covenant

 

During the Term of Employment and for a period of 6 months thereafter
for Sections 5.3.1 and 5.3.2, and a period of 18 months thereafter for Section 5.3.3, regardless of the reason for such termination,
you will not, either alone or in partnership or in conjunction with any Person, whether as principal, agent, employee, director,
officer, shareholder, consultant or in any capacity or manner whatsoever, whether directly or indirectly:

 

5.3.1
carry on or be engaged in, or advise, or give financial assistance to, any business, enterprise or undertaking within Canada that:

 

.1 is involved in the business or in the sale, distribution,
development or supply of any product or service that is the same as or substantially similar to the products or services offered
by the Company as at the date of the termination of your employment (the “Termination Date”); or

 

.2 competes in a substantial or material way with
the Company with respect to any aspect of the Business as at the Termination Date; provided, however, that the foregoing will not
prohibit you from acquiring, solely as an investment and through market purchases, securities of any such enterprise or undertaking
which are publicly traded, so long as you are not part of any control group of such entity and such securities, which if converted,
do not constitute more than 5% of the outstanding voting power of that entity;

    11 

     

    

5.3.2 agree to be employed by any Person that was a Key
Contact as at the Termination Date (but in any case, with whom you have had business contact in the course of your employment with
the Company during the two years prior to the Termination Date ) for any business purpose that is competitive with the Business
in any substantial or material way; or make use of any list or proprietary information of or relating to such Key Contacts for
the purpose of competing with the Company; or be involved in the sale to, solicitation of or servicing of any such Key Contact
where such sale, solicitation or servicing is with respect to services or products which are the same or substantially similar
to or which compete with products or services sold or provided by the Company as at the Termination Date; or otherwise attempt
to interfere with or damage the Company’s business relationship with any such Key Contact; or

 

5.3.3 solicit, divert, entice or take away from the Company
or any Affiliate of the Company with whom you have been actively engaged in business contact in the course of your employment with
the Company in the 18 months prior to the Termination Date or in respect of whom you acquired confidential or proprietary information
during the course of your employment with the Company that the Company has a reasonable need to protect against (a “Protected
Affiliate”), or attempt to do so or solicit for the purpose of doing so, any business of the Company or any Protected Affiliate
of the Company, or any Person that was an employee or contractor of the Company or any Protected Affiliate (but in any case, with
whom you have had business contact in the course of your employment with the Com during the 18 months prior to the Termination
Date) to terminate, discontinue or alter to the detriment of the Company, his, her or its employment or engagement relationship
with the Company or its Protected Affiliates or otherwise attempt to interfere with or damage the Company’s relationship
with any such person.

 

5.4
Provisions Reasonable

 

You hereby acknowledge and agree that:

 

5.4.1 the Company has a material interest in preserving
the relationships it has developed with its Key Contacts against impairment by competitive activities of a former employee;

 

5.4.2 during the course of your employment by the Company,
you will acquire knowledge of, and you will come into contact with, initiate and establish relationships with Key Contacts, and
that in some circumstances you may be the senior or sole representative of the Company or any Affiliate of the Company dealing
with such Persons; and

 

5.4.3 in light of the foregoing, the provisions of Section
5.3 (Restrictive Covenant) are reasonable and necessary for the proper protection of the business, property and goodwill of the
Company and the Business and any Protected Affiliate and you further agree that these restrictions and your agreement to them are
of major importance to the Company, which would not employ or continue to employ you if you did not agree to them.

 

5.5 Right to Use Employee’s Name and Likeness

 

During the Term of Employment, you hereby grant to the Company
the right to use your name, likeness and/or biography in connection with services performed by you under this Agreement and in
connection with the advertising or exploitation of any project with respect to which you perform services for the Company.

    12 

     

    

Article
6 Termination

 

		6.1	Termination by Employee

 

You may resign from your position at any time, but only by giving
the Company at least 30 days prior written notice of the effective date of your resignation (the “Notice
Period”). On the giving of any such notice, the Company may accelerate your resignation, in lieu of the Notice
Period or any part thereof, by notice in writing to you and payment to you of any compensation and continuation of benefits due
to you for the balance of the 30-day Notice Period pursuant to this Agreement, less applicable statutory deductions. You agree
that such acceleration of your resignation shall not constitute termination of your employment by the Company.

 

		6.2	Termination by Company Without Cause

 

The Company may terminate your employment at any time without
Cause (as defined below) in accordance with the terms set out in this Agreement and by giving you written notification of termination.
In the event that your employment is so terminated, you will have the common law duty to mitigate your damages.

 

		6.3	Consequences of Termination Without Cause Unrelated to a Change of Control

 

Subject to Section 6.4, on the giving of any notice referred
to in Section 6.2, the Company shall provide you with the greater of either (i) 3 months’ Base Salary, bonus (3.3), in addition
to 1 month for every year of service (or part thereof) to the company upon and effective at 3 years of employment, or (ii) the
minimum notice or pay in lieu of notice and severance pay, if applicable, that is expressly required by applicable employment standards
legislation, including the ESA. In the case of either Section 6.3(i) or (ii), your participation in Company benefits plans will
be continued for only the minimum period expressly required by applicable employment standards legislation, including the ESA.
Other than as set out in this Section and Section 6.7, you will not be entitled to any additional notice, pay in lieu of notice,
severance or other payments whether pursuant to the common law or otherwise upon termination of your employment without Cause unrelated
to a Change of Control pursuant to this Section 6.3.

 

		6.4	Consequences of Termination Without Cause After a Change of Control

 

On the giving by the Company to you of the written notice referred
to in Section 6.2: (i) at the same time as, or within the twelve (12) month period following, the consummation of a Change of Control,
or (ii) within the thirty (30) day period prior to the date of the consummation of a Change of Control where such Change of Control
was under consideration by the Board at the time of your termination, then the following terms apply in substitution of the compensation
and benefits referred to in Section 6.3 above:

 

		6.4.1	the Company shall provide you with the greater of either (i) 6 months’ Base Salary and bonus (3.3), in addition to 1
month for every year of service (or part thereof) to the company, upon and effective at 3 years of employment, or (ii) the minimum
notice or pay in lieu of notice and severance pay, if applicable, that is expressly required by applicable employment standards
legislation, including the ESA, plus in the case of either Section 6.4.1(i) or (ii), your participation in Company benefits plans
will be continued for only the minimum period expressly required by applicable employment standards legislation, including the
ESA; and

    13 

     

    

		6.4.2	as set out in and subject to the terms of Section 3.5 above, as of the date of the consummation of the Change of Control, any
unvested stock options granted to you under the Option Agreement will vest and be exercisable in accordance with the terms and
conditions of this Option Agreement.

 

Other than as set out in this Section and Section 6.7 below,
you will not be entitled to any additional vesting, notice, pay in lieu of notice, severance or other payments whether pursuant
to the common law or otherwise upon termination of your employment without Cause after a Change of Control pursuant to this Section
6.4.

 

		6.5	Termination in the Event of Death

 

Your employment shall terminate immediately upon your death
and the Company shall pay your estate any amounts which may be due and remaining unpaid at the time of the termination of employment,
in accordance with applicable employment standards legislation, including the ESA.

 

		6.6	Termination by Company for Cause

 

Notwithstanding any other provision in this Agreement, the
Company may at any time summarily terminate your employment, without any obligation to provide notice of pay in lieu of notice,
for “Cause”, in which case you will only be entitled to receive such minimum compensation, benefits continuation,
and any other entitlements as are expressly required by applicable employment standards legislation, including the ESA. In this
Agreement, “Cause” means any of the following:

 

		6.6.1	commission of theft, embezzlement, fraud, obtaining funds or property under false pretenses or similar acts of misconduct with
respect to the property of the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers,
employees or contractors;

 

oral or written representations made by you to the Company
or any Affiliate of the Company with the intent to deceive or mislead; commission of an act of malfeasance, dishonesty or breach
of trust against the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers, employees
or contractors, including a breach by you of any of your covenants or obligations under Section 5.1 (Disclosure of Conflicts of
Interest), Section 5.2 (Avoidance of Conflicts of Interest) or Section 5.3 (Restrictive Covenant);

 

		6.6.2	the entering of a guilty plea by you or your conviction for a serious criminal offence which impacts adversely on the Company
or any Affiliate of the Company;

 

		6.6.3	repeated and continued failure to fulfill your duties or obligations of employment or your breach of any material obligations
and covenants under this Agreement. Termination for such “Cause” shall only occur if you have been given written notice
of such failure to fulfill your duties or obligations and you have been given an opportunity to correct such behavior;

    14 

     

    

		6.6.4	the termination of your employment with POINT Biopharma Corp. other than a termination pursuant to section 6.2; or

 

		6.6.5	any other misconduct or omission that amounts to just cause for summary dismissal at common law. In the event the Company dismisses
you for cause pursuant to this Section 6.6 and, subsequently, a court or arbitrator rules that the Company did not have cause,
you hereby agree that you will only be entitled to damages in an amount equal to the compensation that would have been due to you
had the Company terminated your employment pursuant to Section 6.3 (Consequences of Termination Without Cause), less any amounts
earned by you in mitigation.

 

		6.7	Termination Date and Full Satisfaction

 

“Termination Date” means the earlier of: (i) the
date on which you are notified in writing by the Company of the termination of your employment for any reason, and (ii) the date
on which you notify the Company of your resignation from employment for any reason, but in any case, without regard to any payment
or notice period to which you might then be entitled.

 

It is agreed that as a result of the termination of your employment,
for any reason, you shall not be entitled to any notice, fee, salary, severance or other payments, benefits or damages in excess
of what is specified or provided for in Section 6.1 (Termination by Employee), Section 6.3 (Consequences of Termination Without
Cause Unrelated to a Change of Control), Section 6.4 (Consequences of Termination Without Cause After a Change of Control) and
Section 6.6 (Termination by Company for Cause), whichever is applicable, except that you shall remain entitled to receive all salary
and other amounts, if any, which are then due and owed to you as of the Termination Date, in addition to any accrued but unpaid
vacation pay and any other minimum entitlements expressly required to be provided to you by (and any such minimum entitlements
shall be calculated in accordance with) applicable employment standards legislation, including the ESA. Payment of any amounts
pursuant to Section 6.1 (Termination by Employee), Section 6.3 (Consequences of Termination Without Cause Unrelated to a Change
of Control), Section 6.4 (Consequences of Termination Without Cause After a Change of Control), and Section 6.6 (Termination by
Company for Cause) shall be subject to the withholding of all applicable statutory deductions by the Company. You will be required
to execute a standard release of claims document in a form satisfactory to the Company in order to receive any payments in excess
of those required by applicable employment standards legislation, including the ESA.

    15 

     

    

Article
7 General

 

		7.1	Agreement Confidential

 

Both parties shall keep the terms and conditions of this Agreement
confidential except as may be required to enforce any provision of this Agreement or as may otherwise be required by any law, regulation
or other regulatory or securities requirement.

 

		7.2	Binding Effect

 

This Agreement shall be binding upon and inure to the benefit
of the Company and its successors and assigns. Your rights and obligations contained in this Agreement are personal and such rights,
benefits and obligations shall not be voluntarily or involuntarily assigned, alienated or transferred, whether by operation of
law or otherwise, without the prior written consent of the Company. This Agreement shall otherwise be binding upon and inure to
the benefit of your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, legatees
and permitted assigns.

 

		7.3	Counterparts

 

This Agreement may be executed in several counterparts (including
by fax or electronic transmission), each of which when so executed shall be deemed to be an original and shall have the same force
and effect as an original but such counterparts together shall constitute but one and the same instrument.

 

		7.4	Entire Agreement

 

The terms and conditions of this Agreement are in addition to
and not in substitution for the obligations, duties and responsibilities imposed by law on employees of corporations generally,
and you agree to comply with such obligations, duties and responsibilities. Except as otherwise provided in this Agreement, this
Agreement constitutes the entire agreement between you and the Company and supersedes all prior negotiations, proposals and agreements,
whether oral or written, with respect to the subject matter hereof, and may only be varied by further written agreement signed
by you and the Company. You further acknowledge and agree that you have not relied on any representation made by the Company, or
any of its employees or agents, except as specifically set out in this Agreement.

 

		7.5	Further Assurances

 

Each of the parties hereto will, on demand by the other party
hereto, execute and deliver all such further documents and instruments and do all such further acts and things as the party may
either before or after the execution and delivery of this Agreement reasonably request to evidence, carry out and give full effect
to the terms, conditions, intent and meaning of this Agreement.

 

		7.6	Governing Law

 

This Agreement shall be construed and enforced in accordance
with and be governed by and interpreted in accordance with the laws of the Province of Ontario and the law of Canada applicable
therein, without regard to the principles of conflicts of law. The courts of Ontario (and the Supreme Court of Canada, if necessary)
shall have exclusive jurisdiction to hear and determine all disputes arising hereunder, and each of the parties hereto irrevocably
attorns to the jurisdiction of said courts.

    16 

     

    

		7.7	Independent Legal Advice

 

You acknowledge and agree that the Company has given you the
opportunity to seek, and has recommended that you obtain, independent legal advice with respect to the subject matter of this Agreement
and, further, you hereby represent and warrant to the Company that you have either sought independent legal advice or have waived
your right to obtain such advice.

 

		7.8	Injunctive Relief

 

You acknowledge and agree that any breach or threatened breach
of any of the provisions of, Section 5.1 (Disclosure of Conflicts of Interest), Section 5.2 (Avoidance of Conflicts of Interest),
or Section 5.3 (Restrictive Covenant) could cause irreparable damage to the Company, that such harm could not be adequately compensated
by the Company’s recovery of monetary damages, and that in the event of a breach or threatened breach thereof, the Company
shall have, in addition to any and all remedies at law or in equity, the right to seek an injunction, specific performance or other
equitable relief as well as any equitable accounting of all your profits or benefits arising out of any such breach. It is further
acknowledged and agreed that the remedies of the Company specified in this Section 7.8 are in addition to and not in substitution
for any rights or remedies of the Company at law or in equity and that all such rights and remedies are cumulative and not alternative
and that the Company may have recourse to any one or more of its available rights or remedies as it shall see fit.

 

		7.9	Non-Disparagement

 

You shall not, directly or indirectly, make any disparaging
comments or criticisms (whether of a professional or personal nature) to any Person regarding the Company, any Affiliate of the
Company, the Key Contacts, or their respective directors, officers, employees or contractors (or the terms of any agreement or
arrangement of the Company) or regarding your relationship with the Company or any termination of such relationship which, in each
case, are reasonably expected to result in material damage to the business or reputation of the Company, any Affiliate of the Company,
a Key Contact, or any of their respective directors, officers, employees or contractors.

 

Upon termination of your employment for any reason whatsoever,
you agree that you will not, directly or indirectly, verbally or in writing, criticize, disparage, speak negatively of, or make
any harmful statement about the Company, or its employees, products or services (including but not limited to on any social media
or on Glassdoor or similar websites, blogs, etc.). Further, you agree that you will immediately cease to represent yourself as
being in any way connected with, or interested in, the Company, and will immediately update any social media (including any blogs
or social networking sites, including but not limited to LinkedIn) to reflect this.

    17 

     

    

		7.10	Notice

 

Any notice or other communication required or contemplated to
be given hereunder must be in writing and shall be deemed effective when personally delivered or on the day following the sending
when sent by facsimile transmission, addressed to the appropriate party as set forth below:

 

If to the Employee:

 

Donna
Husack

140 Burnet Street 

Oakville ON L6K 1C2

 

If to the Company:

 

POINT
Biopharma Corp.

22 St. Clair Ave. East, Suite 1201, 

Toronto, ON M4T 2S3

 

Attention: Bill Demers, CFO

 

		7.11	Publicity

 

You shall not, without the prior written consent of the Company,
make or give any public announcements, press releases or statements to the public or the press regarding your Work Product or any
Confidential Information.

 

		7.12	Severability

 

If any provision of this Agreement is determined to be void,
illegal or unenforceable, such provision will be construed to be separate and severable from this Agreement and will not impair
the validity, legality or enforceability of any other provision of this Agreement and the remainder of this Agreement will continue
to be binding on the parties hereto as if such provision had been deleted.

 

It is not the Company’s intention to attempt to contract
out of its obligations or your minimum entitlements under applicable employment standards legislation, including the ESA. Therefore,
notwithstanding anything stated or unstated in this Agreement or in the Company’s policies and procedures, you will not,
under any circumstances, receive anything less than your full entitlements under applicable employment standards legislation, including
the ESA. Any provision of this Agreement or such policies and procedures that provides for anything less than such entitlements
shall be deemed to be replaced by the applicable minimum standard under applicable employment standards legislation, including
the ESA.

 

		7.13	Surviving Obligations

 

Upon termination of this Agreement for any reason, any obligations
which by their terms or nature, must extend beyond the date of termination to be effective shall survive termination of this Agreement.
Without limiting the foregoing, your obligations under Section 5.3 (Restrictive Covenant), Section 5.4 (Provisions Reasonable),
Article 6 (Termination) and Article 7 (General) shall survive and remain in full force and effect following the termination of
this Agreement.

    18 

     

    

		7.14	Waiver

 

Any waiver of any breach or default under this Agreement shall
only be effective if made in writing, signed by the party against whom the waiver is sought to be enforced, and no waiver shall
be implied by any other act or conduct or by any indulgence, delay or omission. Any waiver shall only apply to the specific matter
waived and only in the specific instance in which it is waived.

 

		7.15	Acceptance

 

If the foregoing terms and conditions are acceptable to you,
please indicate your acceptance of and agreement to the terms and conditions of this agreement by signing below on this letter
and on the enclosed copy of this letter in the space provided and by returning the enclosed copy so executed to us. Your execution
and delivery to the Company of the enclosed copy of this letter will create a binding agreement between us.

 

Yours truly,

POINT Biopharma Corp.

 

Per: /s/ Joe McCann

Authorized Signatory

 

Joe McCann, CEO

 

Acknowledged and Agreed:

I acknowledge that I have had sufficient time to thoroughly review this agreement and obtain the advice that I deem appropriate
regarding its terms and conditions. I have read, understand and voluntarily accept employment with POINT Biopharma Corp. on the
terms and conditions set out above.

 

	March 9, 2021	 	      /s/ Donna Husack	 
	Date	 	Donna Husack	 

    19 

     

    

Exhibit
1.1.5: Description of the Business

 

The Company is a clinical stage pharmaceutical company focused
on the development and commercialization of radiotherapeutics and theranostic products. The company will compete in therapeutic
categories related to the use of radiotherapeutics and theranostic products in oncology.

    20 

     

    

Exhibit
2.1: Description of Duties – Vice President Human Resources

 

The Vice President Human Resources reports directly to the Chief
Executive Officer.

 

		1.1.	Top executive responsible for overseeing the overall human resources function in an independent corporation on a global basis.

		1.2.	Responsible for overseeing the planning, development, implementation and administration of the company’s human resources
strategies and programs, including succession planning, compensation and benefits, recruitment, training, leadership development,
talent management, performance management and employee relations programs.

		1.3.	Responsible for establishing long-range human resource strategies and practices for the organization to meet specific business
objectives.

		1.4.	Ensures business processes comply with regulatory and legal requirements globally to minimize risk to the organization.

		1.5.	May provide internal leadership coaching to members of the CEO’s executive staff and interacts with executive-level management
on a peer basis.

		1.6.	May have responsibility for facilities/real estate management.

 

Exhibit 2.3.5: Permitted External Roles

 

		1.	Continue on the Board of Pharmaceutical Science Group (PSG)

    21algs-ex43_785.htm

Exhibit 4.3

Description of Capital Stock

The following summary describes the capital stock of Aligos Therapeutics, Inc. (the “Company,” “we,” “us” and “our”) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors’ rights agreement to which we and certain of our stockholders are parties and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and amended and restated investors’ rights agreement, copies of which are incorporated by reference as Exhibits 3.1, 3.2 and 10.4, respectively, to our Annual Report on Form 10-K. 

General 

Our authorized capital stock consists of 300,000,000 shares of common stock, $0.0001 par value per share, 20,000,000 shares of non-voting common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. 

Common Stock and Non-Voting Common Stock 

Voting Rights

The holders of our common stock and non-voting common stock have identical rights, provided that, (i) except as otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors, and (ii) holders of our common stock have no conversion rights, while holders of our non-voting common stock have the right to convert each share of non-voting common stock into one share of common stock at such holder’s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 4.99% of our common stock immediately prior to and following such conversion, unless otherwise expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased to any other percentage designated by such holder of non-voting common stock upon 61 days’ notice to us or decreased at any time upon notice to us. 

Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66-2/3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, our classified board and director liability. 

Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock and non-voting common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. 

Rights Upon Liquidation

In the event of our liquidation, dissolution or winding up, holders of our common stock and non-voting common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. 

US-DOCS\121972707.2

 

 

Other Rights

Holders of our common stock and non-voting common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock or non-voting common stock. The rights, preferences and privileges of the holders of our common stock and non-voting common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. 

Fully Paid and Nonassessable

All of our outstanding shares of common stock and non-voting common stock are fully paid and nonassessable. 

Preferred Stock 

Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. 

Registration Rights 

Under our amended and restated investors’ rights agreement, certain holders of shares of common stock and non-voting common stock, or their transferees, have the right to require us to register their shares under the Securities Act of 1933, as amended, so that those shares may be publicly resold, and certain holders of shares of common stock and non-voting common stock, or their transferees, have the right to include their shares in any registration statement we file, in each case as described below. 

Form S-1 Demand Registration Rights 

Certain holders of shares of our common stock and non-voting common stock, or their transferees, are entitled to certain Form S-1 demand registration rights. Beginning April 14, 2021, the holders of at least 30% of these shares can request that we register all or a portion of their shares (including the shares of common stock into which any shares of non-voting common stock held by such investors may be converted), so long as such holders request that we register at least 20% of the shares entitled to these demand registration rights and the aggregate proceeds, net of underwriting discounts and commissions, would exceed $20 million if the first offering or $5 million after the first offering. These stockholders may make up to two requests for registration on Form S-1.

Form S-3 Demand Registration Rights 

Certain holders of shares of our common stock and non-voting stock, or their transferees, are entitled to certain Form S-3 demand registration rights. If we are eligible to use a Form S-3 registration statement, the holders of these shares can request that we register all or a portion of their shares on a Form S-3 registration statement if the anticipated aggregate offering price is at least $2 million, net of underwriting discounts and commissions and certain other expenses related to the sale of the shares. These stockholders may make unlimited requests for registration on Form S-3, provided that we are not obligated to effect, or take any action to effect, a registration on Form S-3 if we have effected two registrations on Form S-3 pursuant to requests by these stockholders within the twelve month period immediately preceding such request. 

 

US-DOCS\121972707.2

 

Piggyback Registration Rights 

In the event that we determine to register any of our common stock under the Securities Act of 1933, as amended, (subject to certain exceptions), either for our own account or for the account of other security holders, certain holders of shares of our common stock and non-voting common stock or their transferees will be entitled to certain “piggyback” registration rights allowing the holders to include their shares in such registration, subject to certain marketing and other limitations and the conversion of non-voting common stock into shares of common stock prior to registration thereof. As a result, whenever we propose to file a registration statement under the Securities Act of 1933, as amended, other than with respect to certain registrations, including related to the sale of securities to employees pursuant to employee benefit plans, the offer and sale of convertible debt securities, an SEC Rule 145 transaction, or a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the registerable shares, the holders of these shares are entitled to notice of the registration and have the right to include their shares of common stock in the registration. In an underwritten offering, the underwriters have the right, subject to specified conditions, to limit the number of shares such holders may include. 

Expenses of Registration 

We will pay the registration expenses, excluding underwriting discounts and commissions and certain other expenses, of the holders of the shares registered pursuant to the Form S-1 demand, Form S-3 demand and piggyback registration rights described above, including the reasonable expenses of one counsel for the selling holders not to exceed $50,000. 

Expiration of Registration Rights 

The Form S-1 demand, Form S-3 demand and piggyback registration rights described above will terminate, with respect to any particular stockholder, upon the earlier of (i) three years after the consummation of our initial public offering, (ii)  the date that Rule 144 or another similar exemption under the Securities Act of 1933, as amended, is available to such stockholder for the sale of all of such stockholder’s shares without limitation during a three-month period, or (iii) upon the consummation of a merger or consolidation. 

Anti-takeover Effects of Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware Law 

Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. 

These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. 

Delaware Anti-takeover Statute 

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed “interested stockholders” from engaging in a “business combination” with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an 

 

US-DOCS\121972707.2

 

“interested stockholder” is a person who, together with affiliates and associates, beneficially owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. 

Undesignated Preferred Stock 

The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to institute a change of control of our company. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. 

Special Stockholder Meetings 

Our amended and restated bylaws provide that a special meeting of stockholders may only be called by our board of directors, Chief Executive Officer or, in the absence of a chief executive officer, our President. 

Requirements for Advance Notification of Stockholder Nominations and Proposals 

Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. 

Elimination of Stockholder Action by Written Consent 

Our amended and restated certificate of incorporation and our amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting. 

Classified Board; Election and Removal of Directors; Filling Vacancies 

Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66-2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies will be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of our directors. 

Choice of Forum 

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, our amended and restated bylaws or as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated certificate of incorporation also provides that the 

 

US-DOCS\121972707.2

 

federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act of 1933, as amended. 

We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors and officers. The choice of forum provision requiring that the Court of Chancery of the State of Delaware or the federal district courts of the United States of America be the exclusive forum for certain actions would not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended. 

Our exclusive forum provision does not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders are not deemed to have waived our compliance with these laws, rules and regulations. 

Although our amended and restated certificate of incorporation contains the choice of forum provisions described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. 

Amendment of Certificate of Incorporation Provisions 

The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66-2/3% of the voting power of the then outstanding voting stock. 

The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. 

Nasdaq Global Select Market Listing 

Our common stock is listed on the Nasdaq Global Select Market under the symbol “ALGS.” 

Transfer Agent and Registrar 

The transfer agent and registrar for our common stock is Continental Stock Transfer & Trust Co. The transfer agent and registrar’s address is 1 State Street, 30th Floor, New York, NY 10004. 

 

US-DOCS\121972707.2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]